COMPANY CONTACT:
Cytogen Corporation
Stacy Shearer
Investor Relations
(609) 750-8289
sshearer@cytogen.com

         CYTOGEN AND DRAXIMAGE AGREE TO TERMINATE BRACHYSEED AGREEMENTS

PRINCETON,  N.J.,  (APRIL 8,  2003) -- Cytogen  Corporation  (Nasdaq:  CYTO),  a
product-driven,  oncology-focused biopharmaceutical company, today announced the
amicable   resolution   of  all  open   matters   with   DRAXIMAGE   Inc.,   the
radiopharmaceutical subsidiary of DRAXIS Health Inc. (TSX: DAX, Nasdaq: DRAX).

On  December  5,  2000,  Cytogen  and  DRAXIMAGE  entered  into  a  License  and
Distribution  Agreement and a Product  Manufacturing  and Supply  Agreement (the
"BrachySeed  Agreements") with respect to both of DRAXIS'  BrachySeed(TM)  I-125
and  BrachySeed(TM)  Pd-103  products.  Subsequently,  the parties have mutually
agreed to terminate the BrachySeed  Agreements,  maintain the confidentiality of
each other's proprietary information and have released each other from all other
liability  with  respect to any claims under such  agreements.  The parties have
also agreed to certain  indemnification  obligations with respect to third party
claims.

Cytogen and DRAXIMAGE are coordinating  efforts for an orderly transition of the
brachytherapy  business  in  order  to  assure  that  customer  service  can  be
maintained and that no patient care is disrupted as a result of the changeover.

"We believe this  resolution  meets the  objectives of both companies and allows
each of our  management  teams to focus on  continuing  to build our  respective
businesses,"  said Michael D. Becker,  president and chief executive  officer of
Cytogen  Corporation.  "Cytogen will now focus on its  proprietary  and licensed
products, such as ProstaScint(R),  Quadramet(R) and NMP22(R) BladderChek(TM), as
well  as  late-stage  opportunities,  such  as  Combidex(R),  and  our  evolving
development pipeline based on prostate specific membrane antigen."

About Cytogen Corporation

Cytogen  Corporation  of  Princeton,  NJ is a  product-driven,  oncology-focused
biopharmaceutical  company.  Cytogen markets  proprietary and licensed  oncology
products  through  its  in-house   specialty  sales  force:   ProstaScint(R)  (a
monoclonal  antibody-based  imaging agent used to image the extent and spread of
prostate  cancer)  and  NMP22(R)  BladderChek(TM)  (a  point-of-care,  in  vitro
diagnostic test for bladder cancer). Cytogen has also developed Quadramet(R),  a
skeletal targeting therapeutic  radiopharmaceutical  for the relief of bone pain
in prostate and other types of cancer,  for which the company receives royalties
on product sales through Berlex Laboratories,  the U.S. affiliate of Schering AG
Germany,  which markets the product in the United States.  Cytogen has exclusive
U.S. marketing rights to Combidex(R), an ultrasmall superparamagnetic iron oxide
contrast agent for magnetic resonance imaging of lymph nodes. Cytogen's pipeline
comprises  product  candidates  at  various  stages  of  clinical   development,
including  fully human  monoclonal  antibodies and cancer vaccines based on PSMA
(prostate specific membrane antigen) technology,  which was exclusively licensed
from Memorial  Sloan-Kettering  Cancer Center. Cytogen also conducts research in
cell signaling through its AxCell Biosciences  research division in Newtown, PA.





For more  information,  please visit the Company's  website at  www.cytogen.com,
which is not part of this press release.

THIS PRESS RELEASE  CONTAINS  CERTAIN  "FORWARD-LOOKING"  STATEMENTS  WITHIN THE
MEANING OF THE PRIVATE SECURITIES  LITIGATION REFORM ACT OF 1995 AND SECTION 21E
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.  ALL STATEMENTS,  OTHER THAN
STATEMENTS OF  HISTORICAL  FACTS,  INCLUDED IN THIS PRESS RELEASE  REGARDING OUR
STRATEGY,  FUTURE OPERATIONS,  FINANCIAL  POSITION,  FUTURE REVENUES,  PROJECTED
COSTS,  PROSPECTS,  PLANS  AND  OBJECTIVES  OF  MANAGEMENT  ARE  FORWARD-LOOKING
STATEMENTS.   THE  WORDS  "ANTICIPATES,"   "BELIEVES,"  "ESTIMATES,"  "EXPECTS,"
"INTENDS," "MAY," "PLANS,"  "PROJECTS,"  "WILL," "WOULD" AND SIMILAR EXPRESSIONS
ARE  INTENDED  TO  IDENTIFY   FORWARD-LOOKING   STATEMENTS,   ALTHOUGH  NOT  ALL
FORWARD-LOOKING  STATEMENTS  CONTAIN  THESE  IDENTIFYING  WORDS.  SUCH  FORWARD-
LOOKING STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES AND INVESTORS ARE
CAUTIONED NOT TO PUT ANY UNDUE RELIANCE ON ANY  FORWARD-LOOKING  STATEMENT.  THE
COMPANY  CANNOT  GUARANTEE  THAT THE COMPANY  WILL  ACTUALLY  ACHIEVE THE PLANS,
INTENTIONS OR EXPECTATIONS DISCLOSED IN ANY SUCH FORWARD-LOOKING STATEMENTS. THE
COMPANY'S  ACTUAL RESULTS MAY DIFFER  MATERIALLY  FROM THE COMPANY'S  HISTORICAL
RESULTS OF OPERATIONS AND THOSE DISCUSSED IN THE FORWARD-LOOKING  STATEMENTS FOR
VARIOUS REASONS,  INCLUDING,  BUT NOT LIMITED TO, THE COMPANY'S ABILITY TO CARRY
OUT ITS BUSINESS AND FINANCIAL PLANS, TO DETERMINE AND IMPLEMENT THE APPROPRIATE
STRATEGIC INITIATIVE FOR ITS AXCELL BIOSCIENCES SUBSIDIARY,  TO FUND DEVELOPMENT
NECESSARY  FOR EXISTING  PRODUCTS AND TO PURSUE NEW PRODUCT  OPPORTUNITIES,  THE
RISK OF WHETHER PRODUCTS RESULT FROM DEVELOPMENT  ACTIVITIES,  PROTECTION OF ITS
INTELLECTUAL PROPERTY PORTFOLIO,  ABILITY TO INTEGRATE IN-LICENSED PRODUCTS SUCH
AS NMP22(R)  BLADDERCHEK(TM),  ABILITY TO ESTABLISH  AND  SUCCESSFULLY  COMPLETE
CLINICAL  TRIALS WHERE REQUIRED FOR PRODUCT  APPROVAL,  THE RISK ASSOCIATED WITH
OBTAINING  THE  NECESSARY  REGULATORY   APPROVALS,   SHIFTS  IN  THE  REGULATORY
ENVIRONMENT  AFFECTING SALES OF THE COMPANY'S PRODUCTS SUCH AS THIRD-PARTY PAYOR
REIMBURSEMENT  ISSUES,  DEPENDENCE ON THE COMPANY'S  PARTNERS FOR DEVELOPMENT OF
CERTAIN  PROJECTS,  THE  ABILITY  TO OBTAIN  FOREIGN  REGULATORY  APPROVALS  FOR
PRODUCTS AND TO ESTABLISH MARKETING  ARRANGEMENTS IN COUNTRIES WHERE APPROVAL IS
OBTAINED,  AND OTHER FACTORS  DISCUSSED IN THE COMPANY'S  FORM 10-K FOR THE YEAR
ENDED  DECEMBER 31, 2002 AND FROM  TIME-TO-TIME  IN THE COMPANY'S  OTHER FILINGS
WITH THE SECURITIES AND EXCHANGE COMMISSION. ANY FORWARD-LOOKING STATEMENTS MADE
BY THE COMPANY DO NOT REFLECT THE POTENTIAL  IMPACT OF ANY FUTURE  ACQUISITIONS,
MERGERS,  DISPOSITIONS,  JOINT VENTURES OR INVESTMENTS THE COMPANY MAY MAKE. THE
COMPANY DOES NOT ASSUME,  AND SPECIFICALLY  DISCLAIMS,  ANY OBLIGATION TO UPDATE
ANY  FORWARD-LOOKING  STATEMENTS,  AND THESE STATEMENTS  REPRESENT THE COMPANY'S
CURRENT OUTLOOK ONLY AS OF THE DATE GIVEN.

                                       ###